Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel bssl antibodies

An antibody, antigen technology, medical use in the treatment of inflammatory conditions, related pharmaceutical compositions, detection of BSSL and/or diagnosis of BSSL-related diseases, can solve problems such as increasing the risk of secondary infection and complications, Achieving the effect of alleviating the above and other disadvantages, preventing inflammatory conditions

Pending Publication Date: 2022-02-25
LIPUM AB
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] Although the treatment of inflammatory conditions, such as autoinflammatory and autoimmune diseases, has been significantly improved over the years by the introduction of new drugs and classes of drugs, such as antibodies, most regimens and drugs still have in common that they aim at Suppression of the immune system, as is the case with all TNFα inhibitor drugs and corticosteroids
This in turn increases the risk of secondary infections and complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel bssl antibodies
  • Novel bssl antibodies
  • Novel bssl antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 22

[0131] Experimental data presented in Example 22 suggest that the second LCDR may not be important for the interaction with BSSL. Thus, in an embodiment, the isolated antibody or antigen-binding fragment thereof comprises a first HCDR comprising an amino acid sequence according to SEQ ID NO: 7, or having at least 87% of SEQ ID NO: 7, such as at least an amino acid sequence of 87.5% identity, preferably consisting of; a second HCDR comprising an amino acid sequence according to SEQ ID NO:8, or an amino acid sequence having at least 75% identity to SEQ ID NO:8, Preferably consisting of; a third HCDR comprising an amino acid sequence according to SEQ ID NO: 9, or an amino acid sequence having at least 83%, such as at least 91.6%, identity to SEQ ID NO: 9, preferably consisting of Consisting of; a first LCDR comprising, preferably consisting of, an amino acid sequence according to SEQ ID NO: 10, or an amino acid sequence having at least 80% identity to SEQ ID NO: 10; and a third L...

Embodiment approach

[0329] One embodiment relates to an isolated antibody or antigen-binding fragment thereof that specifically binds a bile salt-stimulated lipase (BSSL), such as human BSSL (hBSSL). The antibody or antigen-binding fragment thereof binds at least one of a first epitope and a second epitope identified on the BSSL. The first epitope comprises an amino acid sequence according to SEQ ID NO: 1 or is at least 80%, such as 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 1 The amino acid sequence, preferably consisting of, and the second epitope comprise the amino acid sequence according to SEQ ID NO:2 or have at least 80%, such as 85%, 90%, 95%, 96%, 97% with SEQ ID NO:2 , 98% or 99% identical amino acid sequences.

[0330] In one embodiment, the first epitope comprises an amino acid sequence according to SEQ ID NO: 3 or has at least 80%, such as 85%, 90%, 95%, 96%, 97%, 98% or Amino acid sequences with 99% identity, preferably consisting of them.

[0331] In one embodime...

Embodiment 1-A

[0409] Example 1 - Binding of AS20 IgG to human and mouse BSSL (SPR)

[0410] In this example, the binding of the antibody AS20 mouse-IgG1 (AS20mIgG) to human and mouse BSSL was studied by surface plasmon resonance (SPR). AS20 mIgG (heavy chain variable region (HCVR) SEQ ID NO: 80 and light chain variable region (LCVR) SEQ ID NO: 114) has been raised in mice against the full-length BSSL protein (SEQ ID NO ) purified from human milk. :138) generated. Reactivity to mouse BSSL is unknown.

[0411] Materials and methods

[0412] hBSSL and mBSSL (Table 2) were used together with AS20 mouse IgG1 (AS20 mIgG1 ) (produced in-house, HCVR SEQ ID NO: 80 and LCVR SEQ ID NO: 114) in the experiments described in this example.

[0413] use SPR measurements were performed with a T200 instrument (GE Healthcare). To minimize avidity effects, antibodies were immobilized on the sensor surface and BSSL was injected as the analyte. via amine coupling to CM5 (carboxylated dextran surface) se...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to novel isolated antibodies and antigen-binding fragments thereof that bind to human Bile Salt-Stimulated Lipase (hBSSL). The antibodies and antigen-binding fragments thereof bind to a previously uncharacterized epitope, situated in the N-terminal part of hBSSL and identified as comprising the amino acid residues 7-12 and the amino acid residues 42-55. The present invention also relates to the medical uses of the antibodies and / or the antigen-binding fragments thereof, in particular in treatment of inflammatory conditions, and to related pharmaceutical compositions.

Description

technical field [0001] The present invention relates to novel isolated antibodies and antigen-binding fragments thereof that bind a previously uncharacterized epitope of BSSL located in the N-terminal portion of the bile salt-stimulated lipase (BSSL) protein. This document also relates to the medical use of antibodies and antigen-binding fragments thereof, particularly in the treatment of inflammatory disorders, and to related pharmaceutical compositions. Also disclosed herein is the use of antibodies or antigen-binding fragments thereof as molecular tools in the detection of BSSL and / or the diagnosis of BSSL-related diseases. Background technique [0002] Inflammatory disorders, including autoimmune and autoinflammatory diseases, remain a significant threat to human health. Despite advances in the treatment of inflammatory conditions, improved therapies are still sought. [0003] Inflammatory disorders include a number of disorders and diseases characterized by inflammati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P19/02C07K16/40C12N9/20
CPCA61P19/02C12N9/20C07K16/40C07K2317/33C07K2317/92C07K2317/622C07K2317/24C07K2317/52C07K2319/00C07K2317/94C07K2317/34C07K2317/10A61K2039/505C07K2299/00C07K2317/76A61P29/00A61P1/00C07K2317/565
Inventor O·赫内尔S·林德奎斯特L·伦德伯格H·佩尔松洛斯霍姆
Owner LIPUM AB